Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

Prostate Cancer and Prostatic Diseases advance online publication, February 5 2013.
doi:10.1038/pcan.2013.2

Authors: K Miller, J W Moul, M Gleave, K Fizazi, J B Nelson, T Morris, F E Nathan, S McIntosh, K Pemberton
& C S Higano

Source: Prostate Cancer and Prostatic Diseases - February 5, 2013 Category: Urology & Nephrology Authors: K MillerJ W MoulM GleaveK FizaziJ B NelsonT MorrisF E NathanS McIntoshK PembertonC S Higano Tags: zibotentan ZD4054 non-metastatic castration-resistant Source Type: research